Il-yang Pharmaceuticals’ leukemia treatment Supect (ingredient name: radotinib) was confirmed to be effective for solid cancers like lung cancer.
According to Ilyang Pharmaceuticals on Nov. 15, the company and researchers from Korea University and Sookmyung Women's University have jointly found that Supect increases the ability of immune cells, including natural killer cells, to kill cancer cells for treatment of solid cancers such as lung cancer, breast cancer, and malignant melanoma.
The study revealed that Supect increases the Fas ligand (Fasl) expression in NK cells by 10 to 20 percent and increases the ability to kill cancer cells by signaling through Fas receptors on the surface of cancer cells.
The results of the study will be published in the Journal of Immunology Research.
Supect is a second-generation leukemia treatment and has now entered the phase three clinical trial in China. It already signed export contracts with Russia and neighboring countries and is currently negotiating with pharmaceutical companies in Australia, the U.S., and Europe for technology export.